Letters to the Editor

Weight-Based Levothyroxine Dosage Adjustment for Hypothyroidism

 

Am Fam Physician. 2022 Jan ;105(1):6-7.

Original Article: Hypothyroidism: Diagnosis and Treatment

Issue Date: May 15, 2021

See additional reader comments at: https://www.aafp.org/afp/2021/0515/p605.html

To the Editor: Dr. Wilson and colleagues' excellent article provided a recommendation for the starting dosage of levothyroxine to treat overt hypothyroidism. In nonpregnant patients younger than 60 years with no cardiac disease, mental changes, hypothermia, or stupor, the article recommended initiating a levothyroxine dosage of 1.5 to 1.8 mcg per kg per day. The references cited for that dosage recommended different amounts, including 1.6 mcg per kg per day, 1.6 to 1.8 mcg per kg per day, and 1.6 mcg per kg per day for an average-sized man or woman.1,2

Current guidelines recommend a levothyroxine dosage of 1.6 mcg per kg per day based on ideal body weight or lean body mass instead of actual body weight.3,4 Ideal body weight can be calculated as the weight for height that would generate a body mass index of 24 to 25 kg per m2. Lean body mass is a better predictor of the dosage requirement than actual body weight.5 Without this clarification, some patients may receive a dosage of levothyroxine that is too high.

Author disclosure: No relevant financial relationships.

References

show all references

1. Chaker L, Bianco AC, Jonklaas J, et al. Hypothyroidism. Lancet. 2017;390(10101):1550–1562....

2. Vaidya B, Pearce SHS. Management of hypothyroidism in adults. BMJ. 2008;337:a801.

3. Garber JR, Cobin RH, Gharib H, et al.; American Association of Clinical Endocrinologists; American Thyroid Association Taskforce on Hypothyroidism in Adults. Clinical practice guidelines for hypothyroidism in adults [published correction appears in Endocr Pract. 2013;19(1):175]. Endocr Pract. 2012; 18(6): 988–1028.

4. McDermott MT. Hypothyroidism. Ann Intern Med. 2020;173(1):ITC1–ITC16.

5. Santini F, Pinchera A, Marsili A, et al. Lean body mass is a major determinant of levothyroxine dosage in the treatment of thyroid diseases. J Clin Endocrinol Metab. 2005;90(1):124–127.

In Reply: We thank Dr. Muncie for the opportunity to clarify the starting dosage of levothyroxine in patients with overt hypothyroidism. The need for a dosing adjustment based on weight is clinically relevant because of the high prevalence of obesity among adults in the United States.

Although a starting dosage of 1.6 to 1.8 mcg per kg per day can be appropriate in patients with a body mass index of less than 26 kg per m2, weight-based dosing of levothyroxine may inappropriately overdose patients who are overweight and obese.1,2 A lower starting dosage may help bring patients' thyroid-stimulating hormone (TSH) levels into normal range more quickly. Currently, there is no clear, high-level guideline on how to best adjust the starting dosage in patients with a body mass index greater than 30 kg per m2. Strategies include using the ideal body weight or considering the body mass index as a coefficient. Monitoring TSH levels every six to eight weeks and adjusting levothyroxine dosages until the TSH reaches goal are critical to avoid iatrogenic hyperthyroidism or under-replacement. As noted in the article, it is important to regularly monitor the TSH level until it is in the normal range, then make future adjustments based on symptoms or periodic testing.

Author disclosure: No relevant financial relationships.

References

1. Chaker L, Bianco AC, Jonklaas J, et al. Hypothyroidism. Lancet. 2017;390(10101):1550–1562.

2. Papoian V, Ylli D, Felger EA, et al. Evaluation of thyroid hormone replacement dosing in overweight and obese patients after a thyroidectomy. Thyroid. 2019;29(11):1558–1562.

Send letters to afplet@aafp.org, or 11400 Tomahawk Creek Pkwy., Leawood, KS 66211-2680. Include your complete address, e-mail address, and telephone number. Letters should be fewer than 400 words and limited to six references, one table or figure, and three authors.

Letters submitted for publication in AFP must not be submitted to any other publication. Possible conflicts of interest must be disclosed at time of submission. Submission of a letter will be construed as granting the AAFP permission to publish the letter in any of its publications in any form. The editors may edit letters to meet style and space requirements.

This series is coordinated by Kenny Lin, MD, MPH, Associate Deputy Editor for AFP Online.

 

 

Copyright © 2022 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact afpserv@aafp.org for copyright questions and/or permission requests.

Want to use this article elsewhere? Get Permissions

MOST RECENT ISSUE


May 2022

Access the latest issue of American Family Physician

Read the Issue


Email Alerts

Don't miss a single issue. Sign up for the free AFP email table of contents.

Sign Up Now

Navigate this Article